Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta Węgłowska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson, Matthias Augustin. J Am Acad Dermatol 2018
Times Cited: 69
Times Cited: 69
Times Cited
Times Co-cited
Similarity
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, Craig L Leonardi, Yves Poulin, Janice Drew, Luke Peterson, Catherine Arendt, Daniel Burge, Kristian Reich. J Am Acad Dermatol 2018
Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, Craig L Leonardi, Yves Poulin, Janice Drew, Luke Peterson, Catherine Arendt, Daniel Burge, Kristian Reich. J Am Acad Dermatol 2018
73
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
53
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
52
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
52
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B Kimball. J Am Acad Dermatol 2017
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B Kimball. J Am Acad Dermatol 2017
50
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, Bruce Randazzo, Shu Li, Y-K Shen, Kenneth B Gordon. J Am Acad Dermatol 2017
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, Bruce Randazzo, Shu Li, Y-K Shen, Kenneth B Gordon. J Am Acad Dermatol 2017
49
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
49
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
47
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
46
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
46
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
46
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
46
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
44
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
42
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
K A Papp, S Tyring, M Lahfa, J Prinz, C E M Griffiths, A M Nakanishi, R Zitnik, P C M van de Kerkhof, Linda Melvin. Br J Dermatol 2005
K A Papp, S Tyring, M Lahfa, J Prinz, C E M Griffiths, A M Nakanishi, R Zitnik, P C M van de Kerkhof, Linda Melvin. Br J Dermatol 2005
37
Etanercept as monotherapy in patients with psoriasis.
Craig L Leonardi, Jerold L Powers, Robert T Matheson, Bernard S Goffe, Ralph Zitnik, Andrea Wang, Alice B Gottlieb. N Engl J Med 2003
Craig L Leonardi, Jerold L Powers, Robert T Matheson, Bernard S Goffe, Ralph Zitnik, Andrea Wang, Alice B Gottlieb. N Engl J Med 2003
31
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
J-H Saurat, G Stingl, L Dubertret, K Papp, R G Langley, J-P Ortonne, K Unnebrink, M Kaul, A Camez. Br J Dermatol 2008
J-H Saurat, G Stingl, L Dubertret, K Papp, R G Langley, J-P Ortonne, K Unnebrink, M Kaul, A Camez. Br J Dermatol 2008
31
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
A Blauvelt, J C Prinz, A B Gottlieb, K Kingo, H Sofen, M Ruer-Mulard, V Singh, R Pathan, C Papavassilis, S Cooper. Br J Dermatol 2015
A Blauvelt, J C Prinz, A B Gottlieb, K Kingo, H Sofen, M Ruer-Mulard, V Singh, R Pathan, C Papavassilis, S Cooper. Br J Dermatol 2015
31
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Alan Menter, Steven R Feldman, Gerald D Weinstein, Kim Papp, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Cynthia Arnold, Alice B Gottlieb. J Am Acad Dermatol 2007
Alan Menter, Steven R Feldman, Gerald D Weinstein, Kim Papp, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Cynthia Arnold, Alice B Gottlieb. J Am Acad Dermatol 2007
31
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Alice B Gottlieb, Robert Evans, Shu Li, Lisa T Dooley, Cynthia A Guzzo, Daniel Baker, Mohan Bala, Colleen W Marano, Alan Menter. J Am Acad Dermatol 2004
Alice B Gottlieb, Robert Evans, Shu Li, Lisa T Dooley, Cynthia A Guzzo, Daniel Baker, Mohan Bala, Colleen W Marano, Alan Menter. J Am Acad Dermatol 2004
28
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
K Reich, J-P Ortonne, A B Gottlieb, I J Terpstra, G Coteur, C Tasset, P Mease. Br J Dermatol 2012
K Reich, J-P Ortonne, A B Gottlieb, I J Terpstra, G Coteur, C Tasset, P Mease. Br J Dermatol 2012
28
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
28
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
26
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Kenneth B Gordon, Richard G Langley, Craig Leonardi, Darryl Toth, M Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim,[...]. J Am Acad Dermatol 2006
Kenneth B Gordon, Richard G Langley, Craig Leonardi, Darryl Toth, M Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim,[...]. J Am Acad Dermatol 2006
26
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Christopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li,[...]. N Engl J Med 2010
Christopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li,[...]. N Engl J Med 2010
24
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng, Hidemi Nakagawa. J Dermatol 2018
Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng, Hidemi Nakagawa. J Dermatol 2018
32
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
23
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
K Reich, M Gooderham, L Green, A Bewley, Z Zhang, I Khanskaya, R M Day, J Goncalves, K Shah, V Piguet,[...]. J Eur Acad Dermatol Venereol 2017
K Reich, M Gooderham, L Green, A Bewley, Z Zhang, I Khanskaya, R M Day, J Goncalves, K Shah, V Piguet,[...]. J Eur Acad Dermatol Venereol 2017
23
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Kim Papp, Kristian Reich, Craig L Leonardi, Leon Kircik, Sergio Chimenti, Richard G B Langley, ChiaChi Hu, Randall M Stevens, Robert M Day, Kenneth B Gordon,[...]. J Am Acad Dermatol 2015
Kim Papp, Kristian Reich, Craig L Leonardi, Leon Kircik, Sergio Chimenti, Richard G B Langley, ChiaChi Hu, Randall M Stevens, Robert M Day, Kenneth B Gordon,[...]. J Am Acad Dermatol 2015
23
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
21
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
A B Gottlieb, C Leonardi, F Kerdel, S Mehlis, M Olds, D A Williams. Br J Dermatol 2011
A B Gottlieb, C Leonardi, F Kerdel, S Mehlis, M Olds, D A Williams. Br J Dermatol 2011
21
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
C Paul, J Cather, M Gooderham, Y Poulin, U Mrowietz, C Ferrandiz, J Crowley, C Hu, R M Stevens, K Shah,[...]. Br J Dermatol 2015
C Paul, J Cather, M Gooderham, Y Poulin, U Mrowietz, C Ferrandiz, J Crowley, C Hu, R M Stevens, K Shah,[...]. Br J Dermatol 2015
21
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
L Cai, J Gu, J Zheng, M Zheng, G Wang, L-Y Xi, F Hao, X-M Liu, Q-N Sun, Y Wang,[...]. J Eur Acad Dermatol Venereol 2017
L Cai, J Gu, J Zheng, M Zheng, G Wang, L-Y Xi, F Hao, X-M Liu, Q-N Sun, Y Wang,[...]. J Eur Acad Dermatol Venereol 2017
30
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
21
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
R G Langley, T-F Tsai, S Flavin, M Song, B Randazzo, Y Wasfi, J Jiang, S Li, L Puig. Br J Dermatol 2018
R G Langley, T-F Tsai, S Flavin, M Song, B Randazzo, Y Wasfi, J Jiang, S Li, L Puig. Br J Dermatol 2018
20
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D Flynn, Anna Moltó, René-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil,[...]. Ann Rheum Dis 2018
Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D Flynn, Anna Moltó, René-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil,[...]. Ann Rheum Dis 2018
20
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
Atsuyuki Igarashi, Takeshi Kato, Mai Kato, Michael Song, Hidemi Nakagawa. J Dermatol 2012
Atsuyuki Igarashi, Takeshi Kato, Mai Kato, Michael Song, Hidemi Nakagawa. J Dermatol 2012
20
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
20
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Kim A Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, James G Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B Russell, Elizabeth H Z Thompson,[...]. N Engl J Med 2012
Kim A Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, James G Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B Russell, Elizabeth H Z Thompson,[...]. N Engl J Med 2012
20
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.
Akihiko Asahina, Hidemi Nakagawa, Takafumi Etoh, Mamitaro Ohtsuki. J Dermatol 2010
Akihiko Asahina, Hidemi Nakagawa, Takafumi Etoh, Mamitaro Ohtsuki. J Dermatol 2010
18
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
18
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Hidemi Nakagawa, Hiroaki Niiro, Kenji Ootaki. J Dermatol Sci 2016
Hidemi Nakagawa, Hiroaki Niiro, Kenji Ootaki. J Dermatol Sci 2016
18
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
Stephen Tyring, Alice Gottlieb, Kim Papp, Ken Gordon, Craig Leonardi, Andrea Wang, Deepa Lalla, Michael Woolley, Angelika Jahreis, Ralph Zitnik,[...]. Lancet 2006
Stephen Tyring, Alice Gottlieb, Kim Papp, Ken Gordon, Craig Leonardi, Andrea Wang, Deepa Lalla, Michael Woolley, Angelika Jahreis, Ralph Zitnik,[...]. Lancet 2006
17
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
17
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
B E Strober, J J Crowley, P S Yamauchi, M Olds, D A Williams. Br J Dermatol 2011
B E Strober, J J Crowley, P S Yamauchi, M Olds, D A Williams. Br J Dermatol 2011
17
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
U Chaudhari, P Romano, L D Mulcahy, L T Dooley, D G Baker, A B Gottlieb. Lancet 2001
U Chaudhari, P Romano, L D Mulcahy, L T Dooley, D G Baker, A B Gottlieb. Lancet 2001
17
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
P C M van de Kerkhof, S Segaert, M Lahfa, T A Luger, Z Karolyi, A Kaszuba, G Leigheb, F M Camacho, D Forsea, C Zang,[...]. Br J Dermatol 2008
P C M van de Kerkhof, S Segaert, M Lahfa, T A Luger, Z Karolyi, A Kaszuba, G Leigheb, F M Camacho, D Forsea, C Zang,[...]. Br J Dermatol 2008
17
A randomized trial of etanercept as monotherapy for psoriasis.
Alice B Gottlieb, Robert T Matheson, Nicholas Lowe, Gerald G Krueger, Sewon Kang, Bernard S Goffe, Anthony A Gaspari, Mark Ling, Gerald D Weinstein, Anjuli Nayak,[...]. Arch Dermatol 2003
Alice B Gottlieb, Robert T Matheson, Nicholas Lowe, Gerald G Krueger, Sewon Kang, Bernard S Goffe, Anthony A Gaspari, Mark Ling, Gerald D Weinstein, Anjuli Nayak,[...]. Arch Dermatol 2003
17
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Tsen-Fang Tsai, Ji-Chen Ho, Michael Song, Philippe Szapary, Cynthia Guzzo, Yuang-Kuang Shen, Shu Li, Kwang-Joong Kim, Tae-Yoon Kim, Jee-Ho Choi,[...]. J Dermatol Sci 2011
Tsen-Fang Tsai, Ji-Chen Ho, Michael Song, Philippe Szapary, Cynthia Guzzo, Yuang-Kuang Shen, Shu Li, Kwang-Joong Kim, Tae-Yoon Kim, Jee-Ho Choi,[...]. J Dermatol Sci 2011
17
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Kenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C Prinz, Yasmine Wasfi, Shu Li, Yaung-Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich. N Engl J Med 2015
Kenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C Prinz, Yasmine Wasfi, Shu Li, Yaung-Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich. N Engl J Med 2015
17
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.